Why Is Iovance Biotherapeutics (IOVA) Down 9.2% Since Last Earnings Report?Zacks Investment Research • 03/30/23
Iovance Biotherapeutics completes license application submission for advanced melanoma therapy; shares rallyMarket Watch • 03/24/23
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced MelanomaGlobeNewsWire • 03/24/23
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate UpdatesGlobeNewsWire • 02/28/23
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023GlobeNewsWire • 02/21/23
Iovance's stock is down after receiving FDA feedback on application for new melanoma drugMarket Watch • 11/18/22
Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced MelanomaGlobeNewsWire • 11/18/22
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewsWire • 11/10/22
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate UpdatesGlobeNewsWire • 11/03/22
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 3, 2022GlobeNewsWire • 10/24/22